Journal of Clinical Oncology, Vol 14, 1048-1054, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery

H Wada, S Hitomi and T Teramatsu
Department of Chest Disease Research Institute, Kyoto University, Kyoto, Japan.

PURPOSE: We performed a study to determine whether postoperative mild chemotherapy to maintain the patient's quality of life (QOL) and immunoactivity could also prolong survival. SUBJECT AND METHODS: From December 1985 to July 1988, 323 patients with completely resected primary non-small-cell lung cancer (stage I to III) were enrolled. The subjects were randomized into three treatment groups, as follows: cisplatin (CDDP) 50 mg/m2 body surface, vindesine (VDS) 2 to 3 mg/kg body weight for three courses, and 1-year oral administration of tegafur (FT) plus uracil (UFT) 400 mg/kg body weight (CVUft group, 115 patients); 1-year oral administration of UFT 400 mg/kg body weight (Uft group, 108 patients); or surgical treatment only (control group, 100 patients). RESULTS: The overall 5-year survival rates were 60.6% for the CVUft group and 64.1% for the Uft group versus 49.0% for the control group. The results of statistical testing were P = .053 (log- rank test) and P = .044 (generalized Wilcoxon test) among the three groups, P = .083 (log-rank) and P = .074 (Wilcoxon) between the CVUft and the control groups, and P = .022 (log-rank) and P = .019 (Wilcoxon) between the Uft and the control groups, which indicates higher survival rates in the CVUft and the Uft groups compared with the control group. A multivariate statistical analysis on prognostic factors using Cox's proportional hazards model was performed with the following results: P = .037, hazards ratio = 0.64 with a 95% confidence interval (CI) of 0.42 to 0.97 (control v CVUft group); and P = .009, hazards ratio = 0.55 with a 95% CI of 0.36 to 0.86 (control v Uft group). CONCLUSION: Significantly favorable results were obtained in the CVUft and Uft groups compared with surgery alone. These data showed significant prognostic advantages in the postoperative adjuvant chemotherapy groups.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				D. West, A. J.B. Kirk, and J. Dunning Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 488 - 492. [Abstract] [Full Text] [PDF]

				N. Alam, G. Darling, F. A. Shepherd, J. A. Mackay, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Ann. Thorac. Surg., May 1, 2006; 81(5): 1926 - 1936. [Abstract] [Full Text] [PDF]

				I. Park, K. Y. Chung, K. D. Kim, and D. J. Kim Prognostic Factors for Disease-Free Survival in pT2N0 Non-Small Cell Lung Cancer Asian Cardiovasc Thorac Ann, April 1, 2006; 14(2): 139 - 144. [Abstract] [Full Text] [PDF]

				A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]

				C. Hamada, F. Tanaka, M. Ohta, S. Fujimura, K. Kodama, M. Imaizumi, and H. Wada Meta-Analysis of Postoperative Adjuvant Chemotherapy With Tegafur-Uracil in Non-Small-Cell Lung Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4999 - 5006. [Abstract] [Full Text] [PDF]

				J. H. Park, C.-T. Lee, H. W. Lee, H. J. Baek, J. I. Zo, and Y. M. Shim Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1086 - 1091. [Abstract] [Full Text] [PDF]

				K. M.W. Pisters and T. Le Chevalier Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3270 - 3278. [Abstract] [Full Text] [PDF]

				T. Kindwall-Keller, G. A. Otterson, D. Young, A. Neki, T. Criswell, G. Nuovo, R. Soong, R. Diasio, and M. A. Villalona-Calero Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1870 - 1876. [Abstract] [Full Text] [PDF]

				K. Matsuo, K. Hotta, and H. Ueoka They Also Serve Who Only Stand and Wait: Do Individual Clinical Researchers, Too? Hoping for Individual Patient Data As Public Domain J. Clin. Oncol., February 20, 2005; 23(6): 1334 - 1335. [Full Text] [PDF]

				M. Nakagawa, F. Tanaka, N. Tsubota, M. Ohta, M. Takao, H. Wada, and On behalf of the West Japan Study Group for Lung C A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study Ann. Onc., January 1, 2005; 16(1): 75 - 80. [Abstract] [Full Text] [PDF]

				H. Kato, Y. Ichinose, M. Ohta, E. Hata, N. Tsubota, H. Tada, Y. Watanabe, H. Wada, M. Tsuboi, N. Hamajima, et al. A Randomized Trial of Adjuvant Chemotherapy with Uracil-Tegafur for Adenocarcinoma of the Lung N. Engl. J. Med., April 22, 2004; 350(17): 1713 - 1721. [Abstract] [Full Text] [PDF]

				R. B. Diasio Adjuvant Chemotherapy for Adenocarcinoma of the Lung -- Is the Standard of Care Ready for Change? N. Engl. J. Med., April 22, 2004; 350(17): 1777 - 1779. [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				H-C Hsu, C-J Wang, E-Y Huang, and L-M Sun Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors Br. J. Radiol., January 1, 2004; 77(913): 43 - 48. [Abstract] [Full Text] [PDF]

				S. Cykert and N. Phifer Surgical Decisions for Early Stage, Non-Small Cell Lung Cancer: Which Racially Sensitive Perceptions of Cancer Are Likely to Explain Racial Variation in Surgery? Med Decis Making, March 1, 2003; 23(2): 167 - 176. [Abstract] [PDF]

				W. R. Smythe Treatment of Stage I Non-small Cell Lung Carcinoma Chest, January 1, 2003; 123 (2009): 181S - 187S. [Abstract] [Full Text] [PDF]

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				T. Bando, K. Yamagihara, Y. Ohtake, R. Miyahara, F. Tanaka, S. Hasegawa, K. Inui, and H. Wada A new method of segmental resection for primary lung cancer: intermediate results Eur. J. Cardiothorac. Surg., May 1, 2002; 21(5): 894 - 899. [Abstract] [Full Text] [PDF]

				T. Shoji, F. Tanaka, K. Yanagihara, K. Inui, and H. Wada Phase II Study of Repeated Intrapleural Chemotherapy Using Implantable Access System for Management of Malignant Pleural Effusion Chest, March 1, 2002; 121(3): 821 - 824. [Abstract] [Full Text] [PDF]

				H. Ishikura, K. Kondo, T. Miyoshi, H. Kinoshita, Y. Takahashi, H. Fujino, and Y. Monden Suppression of Mediastinal Metastasis by Uracil-Tegafur or cis-Diamminedichloroplatinum(II) Using a Lymphogenous Metastatic Model in a Human Lung Cancer Cell Line Clin. Cancer Res., December 1, 2001; 7(12): 4202 - 4208. [Abstract] [Full Text] [PDF]

				S. M. Keller, S. Adak, H. Wagner, A. Herskovic, R. Komaki, B. J. Brooks, M. C. Perry, R. B. Livingston, D. H. Johnson, and The Eastern Cooperative Oncology Group A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non-Small-Cell Lung Cancer N. Engl. J. Med., October 26, 2000; 343(17): 1217 - 1222. [Abstract] [Full Text] [PDF]

				F. Tanaka, K. Yanagihara, Y. Otake, R. Miyahara, Y. Kawano, T. Nakagawa, T. Shoji, and H. Wada Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend Eur. J. Cardiothorac. Surg., August 1, 2000; 18(2): 147 - 155. [Abstract] [Full Text] [PDF]

				H. Wagner Jr Postoperative Adjuvant Therapy for Patients With Resected Non-Small Cell Lung Cancer: Still Controversial After all These Years Chest, April 1, 2000; 117 (2009): 110S - 118S. [Abstract] [Full Text] [PDF]

				Y. Fujiwara Current Status of Oral Anticancer Drugs in Japan J. Clin. Oncol., October 1, 1999; 17(10): 3362 - 3365. [Full Text] [PDF]

				J. R. Roberts, M. G. Blum, R. Arildsen, D. C. Drinkwater Jr, K. R. Christian, T. A. Powers, and W. H. Merrill Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer Ann. Thorac. Surg., October 1, 1999; 68(4): 1154 - 1158. [Abstract] [Full Text] [PDF]

				G. Maggi and E. Ruffini Advantage of postoperative oral administration of UFT (Tegafur and Uracil) for completely resected p-Stage I-IIIa non-small cell lung cancer (NSCLC) Eur. J. Cardiothorac. Surg., September 1, 1999; 14(3): 263 - 264. [Full Text] [PDF]

				I. Yoshino, R. Nakanishi, T. Osaki, M. Takenoyama, S. Taga, T. Hanagiri, and K. Yasumoto Unfavorable Prognosis of Patients With Stage II Non-small Cell Lung Cancer Associated With Macroscopic Nodal Metastases Chest, July 1, 1999; 116(1): 144 - 149. [Abstract] [Full Text] [PDF]

				S. George, M. J. Schell, F. C. Detterbeck, and M. A. Socinski Adjuvant Chemotherapy for Resected Non-Small Cell Carcinoma of the Lung: Why We Still Don't Know Oncologist, February 1, 1998; 3(1): 35 - 44. [Abstract] [Full Text]